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Abstract: Background: Neoadjuvant chemoradiotherapy 
has a significant role in downstaging cancer. It improves 
the local control of the disease and can make  conservative 
resection of rectal cancer possible.
Methods: We enrolled 114 patients with subperitoneal 
rectal cancer who underwent neoadjuvant chemoradio-
therapy and radical excision with total mesorectal excision 
(TME). The primary endpoint was oncological outcomes 
and the secondary endpoint was surgical outcomes.We 
evaluate the experience of a multidisciplinary team and 
the role of neoadjuvant chemoradiotherapy in integrated 
treatment of cancer of the subperitoneal rectum.
Results: Surgical procedures performed were abdominal 
perineal resection in 4 cases (3.5%), anterior resection in 
89 cases (78%), Hartmann’s procedure in 5 cases (4.4%), 
and ultralow resection with coloanal anastomosis and 
diverting stoma in 16 patients (14%). 
Local recurrence occurred in 6 patients (5.2%), the overall 
survival was 71.9% at 5 years and disease-free survival was 
about 60%.
Conclusions: The effect of pathological downstaging 
amounted to 58.8%, including cPR. The pathologic com-
plete remission occurred in 8.8% of cases.
The outcomes of neoadjuvant therapy can be achieved 
when this treatment is associated with correct surgical 
technique with TME and the prognosis is defined by an 
anatomopathological examination performed according 
to Quirke’s protocol. 
Keywords: Neoadjuvant chemoradiotherapy; Colorectal 
tumors; Rectal cancer
1  Introduction 
Over the past two decades, outcomes in the management 
of rectal cancer have improved thanks to a multidisci-
plinary approach that involves the surgeon, pathologist, 
radiotherapist and oncologist. There have been continu-
ous efforts to improve local control and long-term survival 
in patients with rectal cancer, and the introduction of neo-
adjuvant therapy protocols in the treatment of this tumor 
has permitted the downstaging of the neoplasm in many 
cases. 
Neoadjuvant therapy has also led to the increase of 
number of conservative interventions, as well as improv-
ing the prognosis by reducing the incidence of recurrence 
and increasing survival [1-6]. On the other hand surgery 
alone has a high rate of complications (10-65%) and local 
recurrence (10-29%) [7].
Recently, several studies have generated considera-
ble interest in the neoadjuvant treatment, which consists 
of the administration of chemotherapy combined with 
radiation therapy (RT) before surgery, with the aim of 
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enhancing the local action of radiation and to sterilize the 
nodal micrometastases, thus increasing the possibility of 
achieving  radical oncological surgery and sphincter-sav-
ing operations [8-13].
In patients undergoing pre-operative RT, there is an 
objective response rate of 65-70% and 5-10% of complete 
responses; the pre-operative RT significantly reduces the 
rate of local recurrence and prolongs survival
 
[12,14]. 
The preoperative chemoradiotherapy has a lower tox-
icity because it acts at an earlier stage in respect to the 
development of metastatic cells [15-17].
In this study, we assessed 114 patients with subper-
itoneal rectal cancer whounderwent preoperative neoad-
juvant chemoradiotherapy and total mesorectal excision 
(TME), from January 2004 to December 2013 at Depart-
ment of Advanced Biomedical Sciences, University of 
Naples Federico II, Naples, Italy. We evaluated through 
the experience of a multidisciplinary team in an observa-
tional real-life retrospective study, and the role of neoad-
juvant chemoradiotherapy in the integrated treatment of 
cancer of the lower rectum in the light of oncology and 
clinical factors outcomes. 
2  Methods
From January 2004 to December 2013 at our center were 
admitted 376 patients (206 male and 170 females) with 
colorectal cancer in an observational real-life retrospec-
tive study. Of these 376, 189 patients had adenocarcino-
mas of the colon and 187 patients had adenocarcinomas 
of the rectum. Among them, 150 patients showed a cancer 
of the rectum localized in the subperitoneal space (<12 cm 
from the anal verge). The 150 patients with subperitoneal 
rectal cancer were evaluated  (82 male and 68 female, 
average age 55 years, range 26-75 years) and were submit-
ted to the following examinations: routine blood chem-
istry, research of tumor markers, colonscopy, endorectal 
ultrasound, MRI, CT/PET Total body. 
Ethical approval: The research related to human use 
has been complied with all the relevant national regula-
tions, institutional policies and in accordance the tenets 
of the Helsinki Declaration, and has been approved by 
the authors' institutional review board or equivalent com-
mittee. At the first observation, each patient gave signed 
informed consent to undergot the surgical procedure and 
be a part of the clinical research.
The study protocol had the following exclusion crite-
ria: beyond the intraperitoneal tumor site (> 12 cm from 
the anal verge) (11 cases); histology different from ade-
nocarcinoma (3 squamous cancer of the anus; 2 lympho-
mas); synchronous primitive multiple cancers (MPM) (6 
cases); presence of metastases (8 cases); and T1, T4 and 
T2N0 (6 cases). 
Of the 150 patients, 114 patients were enrolled and 
treated with neoadjuvant therapy.
The synthesis before and after neoadjuvant treatment 
of 114 patients is reported in Table 1.
The treatment given to patients is constituted by one 
of concomitant chemotherapy scheme [18,19].
2.1  External radiation therapy (RT) 
Radiation treatment was given using a linear accelerator 
(6-25 MV) and isocentric technique of 3 fields (one poste-
rior and 2 lateral) with a total dose of 50.4Gy (25 daily frac-
tions of 1.8Gy to the pelvis plus 3 additional daily fractions 
of 1.8Gy to the tumor). The entire treatment had a duration 
of 28 days. 
2.2  Chemotherapy (CHT) 
Continuous infusion i.v. with elastomeric pump of 5-fluo-
rouracil at dose of 225 mg/m2 for the duration of the radia-
Table 1: Demographic, clinical and surgical procedures in 114 
patients
Gender; No (%):
Male
Female
65 (57)
49 (42.9)
Range of average age 55.0 (26-75)
Follow up  (months) 39.4 (2.2-151.6)
Tumor level, No (%):
High
Mid
Low
0      
58 (50.9)
56 (49.1)
Surgical Procedure, No (%):
Abdominal perineal amputation
Low anterior resection
Hartmann                   
Ultra low anterior resection with  
anastomosis coloanal 
4 (3.5)
89 (78.0)
5 (4.4)
16 (14.0)
The local recurrence at 5 years, No (%):  6 (5.2)
The overall survival at 5 years, No (%): 82 (71.9)
Disease-free survival at 5 years, No (%): 68 (59.6)
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tion treatment. Two boluses i.v. week of oxaliplatin at dose 
of 60 mg/m2.
The patients were re-admitted at our center 4-6 weeks 
after the end of neoadjuvant therapy in order to perform 
restaging and undergo surgery between 6th and 8th week 
after the end of preoperative chemoradiotherapy. 
For all patients at the time of initial staging, we 
assessed whether or not to perform a conservative surgery 
of the sphincter function, essentially based on the dis-
tance of the tumor from the anal verge.
The follow-up after surgery was standard with six-
monthly checks for at least 5 years.
All patients were followed up by the surgeon, special-
ist oncologist, and radiotherapist, and were subjected to 
careful clinical evaluation, blood chemistry with evalua-
tion of the levels of CEA, and chest X-ray. 
3  Results 
We enrolled 114 consecutive patients, 65 were male and 
49 female with a mean age 55 years and range 26-75 years. 
All cases had histologically determined adenocarcinoma 
of the rectum. They were considered only when the rectal 
cancer localization was ≤ 12 cm from the anal verge.
All patients underwent clinical-laboratory weekly 
monitoring during the course of concomitant chemo-
therapy, which showed no toxic effects, with a perfor-
mance status of ECOG grade 0 (patient physically active 
can perform normal activities without restriction). Only 
two patients presented a moderate neutropenia. All 114 
patients completed the set cycle. 
The surgical procedures performed were: abdominal 
perineal resection in 4 cases (3.5%), anterior resection in 
89 cases (78%), Hartmann’s procedure in 5 cases (4.4%), 
and ultralow resection with coloanal anastomosis and 
diverting stoma in 16 patients (14%) (Table 1). 
The mean number of lymph nodes examined was 12; 
the hospital stay was 9-25 days. Seventeen patients had 
postoperative complications: postoperative wound dehis-
cence in 3 (2.6%) patients, anastomotic leak in 9 (7.9%) 
patients, major cardiovascular complications in 5 (4.4%) 
patients (Table 2). 
In all 114 patients the resection margins assessed with 
pathologic examination of the surgical specimen had no 
residual tumor cells. 
During follow-up, we detected two cases of local 
recurrence (1.8%) at 6 and 15 months respectively.  Both 
patients had lymph node recurrence after surgery, and 
one of them developed liver metastases. The local recur-
rence occurred in 6 patients (5.2%) at 5 years, the overall 
survival at 5 years was observed in 82 (71.9%) patients and 
disease-free survival at 5 years in 68 patients (59.6%).
4  Conclusion
In recent years, the use of neoadjuvant chemoradiother-
apy has increased in the perioperative treatment of rectal 
cancer [20-22].
 
Several studies show that the combination 
of a “short course” of neoadjuvant radiotherapy and total 
mesorectal excision results in a better local control than 
only TME [21]. In addition, the neoadjuvant chemoradi-
otherapy has been introduced in the treatment of locally 
advanced rectal cancer to improve the preservation of the 
anal sphincter [14,22-24].
 
In fact, when the rectal cancer 
is locally advanced at diagnosis, recurrence after surgical 
resection occurs in a range of 50% to 70% of cases and is 
characterized by the early onset of distant metastases [25]. 
The neoadjuvant chemoradiotherapy is part of a safe and 
efficient multimodal treatment of rectal cancer. It shows 
significant benefits in terms of reducing the tumor volume 
and less compromise to the neoplastic lymph node, thus 
confirming the concept of down staging. 
In this study, the effect of pathological down staging 
amounted to 58.8%, including cPR. The pathologic com-
plete remission occurred in 8.8% of cases. Patients who 
had a complete pathological remission have had good out-
comes in terms of OS and DFS (71,3% and 60 %, respec-
tively).
In locally advanced rectal carcinoma, this combined 
treatment approach aims to improve resectability, local 
control and overall survival. It does so by reducing the 
tumor volume thus favoring surgical resection and long-
term oncological results [26-28].
In our experience we found a clinical and instrumen-
tal down staging in 59 patients (51.75%). This finding is in 
agreement with literature, the neoadjuvant treatment for 
carcinoma of the rectum can cause a down staging which 
permits an increase of conservation of the sphincter func-
tion [21-24,29-31].
Table 2: Postoperative complication in 17 patients.
Postoperative complications, n (%):
Wound dehiscence 3 (2.6%) 
Anastomotic leak 9 (7.9%)
Major cardiovascular complications 5 (4.4%) 
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Many trials also show that the neoadjuvant chemo-
radiotherapy appears associated with a decrease in the 
rate of local recurrence and to an increase in the overall 
survival rate [18]. However, these data are not accepted 
univocally as some authors argue that the neoadjuvant 
chemoradiotherapy, though it determines a down staging 
and, sometimes, a complete “eradication” of the tumor 
histology, is complicated by high toxicity and a high rate 
of anastomotic leak [32].
In agreement with this finding, in patients subjected 
to ultralow colo-rectal anastomosis we always made a 
temporary ileostomy [33]. 
Some authors emphasize the role of lymph nodes 
involvement detected on the histological sample. In fact 
in patients treated with preoperative chemoradiotherapy 
the presence of positive lymph nodes in the histologi-
cal sample would be associated with a worse prognosis 
[34,35].
 
Hence the importance of intraoperative lymph 
node metastases [36]. 
In our study, the preoperative staging of rectal cancer 
was performed with the digital rectal examination, trans-
rectal ultrasound, colonoscopy and magnetic resonance 
imaging (MRI).
Nowadays EUS is considered very accurate for T 
staging, because it can precisely define the degree of 
tumor penetration into the various layers of the rectal wall 
[37-41]. MRI is the best method to define distance of the 
mesorectal fascia from the lateral margin of the tumor and 
so to determine which patients can benefit from neoadju-
vant therapy. Moreover, its accuracy is greater than ultra-
sonography in identifying the tumors [35, 42-47].
The pathological complete response occurred in 10 
patients (8.8%), like observed by Grann et al. in 9% of 
cases [9]. However, if the cancer has been shown to have 
a pathological downstaging, the latter can provide related 
benefits to the resection of the tumor and the improve-
ment of the oncological results [26-27]. 
The final objective of preoperative chemoradiother-
apy was the pathological complete remission. The best 
outcomes of neoadjuvant therapy can be achieved when 
this treatment is associated with a correct surgical tech-
nique with TME and the prognosis is defined by an anato-
mopathological examination performed according to 
Quirke’s protocol. 
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